Johnson & Johnson completed the acquisition of Ambrx Biopharma Inc. from a group of shareholders.
Centerview Partners LLC is acting as lead financial advisor and fairness opinion provider and Cantor Fitzgerald & Co. is acting as financial advisor to Ambrx; Ray Bogenrief, Timothy F. Nelson, Maria Raptis, Graham Robinson Jack P. Rossman, Resa K. Schlossberg, Moshe Spinowitz and Chadé Severin of Skadden, Arps, Slate, Meagher & Flom LLP are serving as legal counsels. Robert I. Townsend, III, Sanjay Murti and Jin-Kyu Baek of Cravath, Swaine & Moore LLP are legal advisors to Johnson & Johnson. Innisfree M&A Incorporated acted as proxy solicitor to Ambrx Biopharma and Innisfree will receive approximately $40,000 for the service. Equiniti Trust Company acted as transfer agent to Ambrx Biopharma. Ambrx has agreed to pay Centerview an aggregate fee of approximately $29.9 million, $1 million of which was payable upon the rendering of Centerview?s opinion and the remainder of which is payable contingent upon consummation of the Merger. Uale Taotafa and Michael Hostetler of Wilson Sonsini Goodrich & Rosati acted as legal advisors to Ambrx Biopharma.
Johnson & Johnson (NYSE:JNJ) completed the acquisition of Ambrx Biopharma Inc. (NasdaqGS:AMAM) from a group of shareholders on March 7, 2024. Transaction was fully funded by Johnson & Johnson through cash on hand.